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Background: In patients with metastatic melanoma and KIT amplifications and/or mutations, therapy with imatinib
mesylate may prolong survival. 18F-labeled 2-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT may be used to assess
metabolic response. We investigated associations of metabolic response, mutational status, progression-free survival
and overall survival in this population.
Methods: Baseline and 4-week follow-up 18F-FDG-PET/CT were evaluated in 17 patients with metastatic melanoma
and KIT amplifications and/or mutations treated with imatinib in a multicenter phase II clinical trial. The maximum
standardized uptake values (SUVmax) were measured in up to 10 lesions on each scan. Metabolic response was
classified using modified EORTC criteria. Each patient had a diagnostic CT or MR at baseline, after 6 weeks of therapy
and then at intervals of 2 months and anatomic response was classified using RECIST 1.0. Median follow-up was
9.8 months.
Results: Partial metabolic response (PMR), stable metabolic disease (SMD) and progressive metabolic disease (PMD)
was seen in 5 (29%), 5 (29%), and 7 (41%) patients respectively. Five patients (29%) had a KIT mutation in exon 11, four
of whom (80%) had PMR while 1 (20%) had SMD. Twelve patients (71%) did not have a KIT mutation in exon 11, and
only 1 (8%) had PMR, 4 (33%) had SMD and 7 (58%) had PMD. There was agreement of metabolic and anatomic
classification in 12 of 17 patients (71%). Four of 17 patients (24%) had PR on both metabolic and anatomic imaging
and all had a KIT mutation in exon 11. Survival of patients with PMD was lower than with SMD or PMR.
Conclusions: Metabolic response by 18F-FDG-PET/CT is associated with mutational status in metastatic melanoma
patients treated with imatinib. 18F-FDG-PET/CT may be a predictor of outcome, although a larger study is needed to
verify this.
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Malignant melanoma is a spectrum of diseases associ-
ated with several genetic aberrations. Mucosal and acral
melanoma arising from sites such as the palms, soles
and nail beds as well as cutaneous melanoma arising
from chronically sun-damaged skin are forms of the
disease with different but overlapping oncogenes and
biologic behavior [1-5] that have recently been found to
harbor KIT mutations [6-10]. The majority of these
mutations occur in exon 11 at the juxtamembrane
portion of the protein, which predicts responsiveness to
imatinib mesylate [11].
Imatinib mesylate (Gleevec) is a protein-tyrosine kinase
inhibitor that inhibits platelet-derived growth factor and
stem cell factor mediated cellular processes. It can also
inhibit proliferation and induce apoptosis in Bcr-Abl
positive cells or cells with a KIT mutation including
melanoma [12]. In the past, imatinib mesylate has been
successfully used to treat patients with gastrointestinal
stromal tumor (GIST), where malignancy is associated
with a KIT mutation [13-15]. Imaging in patients with GIST
often includes 18F-labeled 2-fluoro-2-deoxy-D-glucose
(18F-FDG) positron emission tomography/computed
tomography (PET/CT), which can show metabolically
active disease and may be more effective for evaluating
therapeutic response to tyrosine kinase inhibition than
anatomic imaging [16-20]. Further, changes in tumor
metabolism may predict outcome.
In GIST, the majority of KIT mutations occur in exon
11 near the N-terminus. In contrast, melanoma patients
have a higher prevalence of KIT mutations in exon 11
near the C-terminus as well as KIT mutations in exon 13
and exon 17, which may confer resistance to imatinib
therapy [7]. Although preliminary results in the literature
suggest imatinib therapy may be helpful for the treatment
of melanoma [21], this may not be the case for all patients
with melanoma despite the presence of a KIT mutation.
In particular, recent studies by Woodman et al. and
Antonescu et al. suggest that the L576P mutation in exon
11, the most common KIT mutation in melanoma, may
induce structural changes resulting in resistance to ima-
tinib therapy compared with other tyrosine kinase inhibi-
tors such as dasatinib [22-24].
We previously suggested that imatinib can be effective
when melanoma tumors harbor KIT mutations [25]. The
aim of this study was to provide a detailed sub-analysis
of the 18F-FDG-PET/CT data acquired during the course
of the previously reported clinical trial [25]. Specifically,
our aim was to assess the metabolic response of patients
with metastatic melanoma and a KIT mutation and/or
amplification treated with imatinib using 18F-FDG-PET/CT
and to investigate the association of 18F-FDG uptake with
mutational status, time-to-progression (TTP) and overall
survival (OS).Methods
Study description
The institutional review boards of the sites participating
in a phase II multicenter clinical trial of imatinib in
metastatic melanoma with KIT amplifications and/or
mutations approved the study before patient enrollment
and continuing approval was maintained throughout the
study (This clinical trial was approved by the Dana-
Farber/Harvard Cancer Center IRB).
Prior to enrollment in the trial, KIT mutational status
was determined by tumor biopsy, followed by polymerase
chain reaction, high performance liquid chromatography
and DNA sequencing, with amplicons arising from exons
9, 11, 13 and 17. KIT gene amplification was assessed by
quantitative polymerase chain reaction, where the thresh-
old for increased KIT copy number relative to normal
tissue was established using the 95% confidence level
according to Chebychev’s inequality and the threshold for
positive was 5.29 copies of KIT relative to GAPDH. KIT
gene copy number was measured in relationship to a
chromosome 2 peri-centromeric probe, corresponding to
a region rarely subject to gain or loss in melanoma. A
sample (or histologically distinctive region) was scored as
amplified if the ratio of probe/centromere was >1.5
(highly-amplified >5.0). Oncogene mutation screened was
also done on pre-treatment tissue in all patients using a
mass spectroscopy system (Sequenom, San Diego, CA)
and a panel of 643 hotspot mutations across 53 cancer
genes.
Seventeen patients had baseline and follow-up 18F-
FDG-PET/CT after one month of therapy. Metabolic
tumor response was classified using modified European
Organisation for Research and Treatment of Cancer
(EORTC) criteria [26]. Anatomic tumor response was
classified according to the best response achieved using
Response Evaluation Criteria in Solid Tumors (RECIST)
1.0 applied to diagnostic CT or MR images obtained
after 6 weeks of therapy and then at intervals of 2
months. The clinical trial methods have been previously
described [25]. Choi criteria was not performed as the
CT scans were acquired according to each institution’s
standard of care in this multicenter trial with no
standardization of the dosage and timing of contrast
media [17].
PET/CT acquisition and analysis
Patients fasted for 6 hours prior to the 18F-FDG-PET/CT.
Each 18F-FDG-PET/CT was acquired approximately 60
minutes (mean: 62 min, range: 56 min – 70 min) after the
intravenous administration of approximately 20 mCi 18F-
FDG (mean: 20.1 mCi, range 17.6 mCi – 22.1 mCi).
Whole-body imaging was performed from the skull vertex
through the toes using a combined PET/CT scanner with
images corrected for detector efficiency, attenuation,
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maintained across participating institutions by adherence
to a standard quality assurance program at each site in
accordance with NCI consensus guidelines [27]. All 18F-
FDG-PET/CT images acquired were transferred to the
Dana-Farber Cancer Institute after de-identification for
central quality control and analysis. Two nuclear medicine
physicians evaluated each study for extent and change of
18F-FDG-avid disease without knowledge of the muta-
tional analysis, RECIST classification, or outcome. Final
results were based on consensus. For each subject, up to
10 target lesions with the greatest FDG-avidity were
identified on the baseline scans and analyzed on both the
baseline and follow-up studies. Tumor FDG uptake was
quantified using the maximum standardized uptake value
(SUVmax). For each subject, the SUVmax of all target
lesions was summed at each time point and the relative
change in the summed SUVmax was used to assess
metabolic response where: partial metabolic response
(PMR) ≤ −25% < stable metabolic disease (SMD) < +25% ≤
progressive metabolic disease (PMD). The appearance
of a new FDG-avid lesion in the post-treatment scans
supersedes the relative change and results in PMD.
Conversely, the complete resolution of all FDG-avid le-
sions in the post-treatment scans results in complete
metabolic response (CMR).Statistical methods
The best overall response rate was defined as the propor-
tion of patients with at least partial response as best
response to therapy. The disease-control rate was defined
as the proportion of patients who achieved complete
response, partial response, or stable disease lasting at least
12 weeks as their best response to therapy. The agreement
of response- and disease-control rate classifications based
on metabolic response and RECIST 1.0 best overall
response was conducted using McNemar’s test. The rela-
tionship between overall metabolic response and muta-
tional status was explored using Fisher’s exact test. As
there was not sufficient documentation of the location of
biopsied lesions in this multi-center study, the overall
metabolic response of the patient based on all lesions was
compared to mutational status rather than the individual
response of the biopsied lesion.
Time-to-progression (TTP) was defined as the time
interval from study enrollment to the date of first docu-
mented disease progression. The follow-up of patients
who died without disease progression was censored at the
date of death; follow-up of patients who had not pro-
gressed at the time of the analysis was censored at the date
of the last study assessment. Overall survival (OS) was
defined as the time from study enrollment to death from
any cause. The follow-up of patients who were alive at thetime of data analysis was censored at the last date of vital
status.
The distributions of TTP and OS are presented using
the method of Kaplan-Meier, with point-wise, 95% confi-
dence intervals estimated using log(−log(survival)) meth-
odology. Comparisons of TTP and OS according to type
of melanoma or mutational status were made using the
log-rank test. To avoid bias, comparisons of TTP and
OS according to metabolic response classification were
conducted using one-month conditional landmark ana-
lyses [28]. Patients who were alive and progression-free
at the time of the one-month metabolic tumor assess-
ment were followed forward in time; patients with rapid
anatomic progression of disease within one month were
removed. Thus, 3 patients with rapid, anatomic progres-
sion prior to the one-month 18F-FDG-PET/CT were
removed from this portion of the analysis. TTP and OS
were then compared according to metabolic response
categories using the log-rank test. Statistical significance
was defined as p < 0.05; there were no corrections for
multiple comparisons.
Results
Nine medical centers participated in the phase II clinical
trial between July 6, 2006 and March 1, 2011. Seventeen
patients had baseline and follow-up 18F-FDG-PET/CT.
Of the 17 patients with 18F-FDG-PET/CT included in
the study, 7/17 (41%) had a KIT mutation, 5 of which
were in exon 11 and 2 of which were in exon 13 or 17,
while 10/17 (59%) had KIT amplification (Table 1).
When there was both a KIT mutation and amplification,
patients were classified as having a mutation for the pur-
poses of analysis. At the time of enrollment, all patients
had metastatic disease and a history of cancer-directed
surgery. The median TTP was 4.7 months (95% CI: 1.3
to 7.4 months) and was independent of melanoma type
(log-rank p = 0.98). TTP was similar for patients with a
KIT mutation, or amplification (log-rank p = 0.33).
Median OS was 12.9 months for patients with a KIT
mutation in exon 11 (95% CI: 5.5 to ∞), 11.7 months for
patients with a KIT gene amplification (95% CI: 2.8 to
16.2) and 10.4 months for patients with another type of
mutation (95% CI: 1.5 to 19.3). Interestingly, the one
patient with a KIT mutation in exon 17 did compara-
tively well with OS of 19.3 months (Table 1) while the 3
patients with the most rapid progression had amplifica-
tion (TTP 1.0 and 0.9 months) and a KIT mutation in
exon 13 (TTP 0.9 months).
Figure 1 shows waterfall plots of metabolic response
by lesion and patient using 18F-FDG-PET/CT. PMR was
seen in 5 of 17 patients (29%), SMD was seen in 5 of 17
patients (29%), and PMD was seen in 7 of 17 patients
(41%). Figure 2 shows illustrative images of a patient
with both PMR and anatomic PR compared with a
Table 1 Patient characteristics and response assessment




Female 79 Exon 11 insertion PYD577-582 4.7 12.9 PMR PR
Female 61 Exon 17 D820Y 10.2 19. 3 SMD PR
Female 69 Amplified 7.4 8.8 SMD PD
Male 57 Amplified 5.0 11.5 PMD PD
Female 62 Amplified 2.6 11.9 SMD PD
Male 69 Amplified 5.8 16.2 PMR PD
Female 81 Amplified 1.0 3.8 PMD PD
Female 72 Amplified 1.3 9.8 PMD PD
Female 55 Amplified 10.6 18.3 SMD SD
Female 59 Amplified 0.9 2.8 PMD PD
Female 59 Exon 11 L576P 27.1 27.1 PMR PR
Female 75 Amplified 5.6 12.5 PMD SD
Female 47 Exon 11 L576P 2.6 7.3 PMR PR
Male 84 Amplified 1.6 21.8 PMD PD
Female 53 Exon 11 deletion WKVVE557-560 10.6 24.3 SMD SD
Male 66 Exon 13 K642E 0.9 1.5 PMD PD
Female 66 Exon 11 L576P 3.4 5.5 PMR PR
PMR = Partial Metabolic Response, SMD = Stable Metabolic Disease, PMD = Progressive Metabolic Disease, PR = Partial Response, SD = Stable Disease,
PD = Progressive Disease, TTP = Time to Progression.
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of therapy. There was agreement of metabolic and ana-
tomic response classification in 12 of 17 patients (71%,
95% CI: 44% to 90%). For the 5 patients where meta-
bolic and anatomic classification did not agree, the
response to therapy using RECIST 1.0 and anatomic
imaging after 6 weeks of therapy was slightly more
likely to show PD than metabolic imaging obtained
after 4 weeks of therapy.
Figure 3 shows the conditional landmark analyses of
TTP and OS by metabolic response. Patients classified
with PMR or SMD had significantly longer TTP than
those with PMD (6.6 months vs. 3.3 months; log-rank
p = 0.04). However, there was no evidence of a differ-
ence in overall survival (log-rank p = 0.53).
There was an association between metabolic response
and KIT mutational status (Fisher’s exact p-value = 0.03).
Five of 17 patients (29%, 95% CI: 10% to 56%) had a
KIT mutation in exon 11. Of these 5 patients, 4 (80%)
had PMR and 1 (20%) had SMD. Twelve of 17 patients
(71%) did not have a KIT mutation in exon 11 (2 with
other mutation and 10 KIT amplified), and only 1 (8%)
had PMR, 4 (33%) had SMD and 7 (58%) had PMD.
Four of 17 patients (24%) had PMR and PR with
anatomic imaging and all of these patients had a KIT
mutation in exon 11. At the time of the data analysis, 4
of 17 patients remained alive and 2 of them (50%) had
a KIT mutation in exon 11.Discussion
In 2013, it is estimated that 76,690 new cases of malig-
nant melanoma were diagnosed in the United States and
there were 9,480 deaths from the disease [29]. Since
prognosis depends on disease histology and the extent of
metastases, among other factors, anatomic and meta-
bolic imaging play a key role in patient evaluation. Spe-
cifically, ultrasound and lymphoscintigraphy are helpful
for the evaluation of lymph node involvement [30,31].
Diagnostic CT is used for the detection of metastases
particularly to the lungs, lymph nodes and liver while
MRI is used to evaluate the brain, meninges and spinal
cord as well as to clarify indeterminate CT lesions [32].
The role of 18F-FDG-PET/CT has evolved in recent
years. 18F-FDG-PET/CT is more accurate than anatomic
imaging alone for the detection of metastases [32-35],
and can lead to change in patient management [36,37].
Surgical excision may be curative for disease confined to
a thin lesion (<1 mm); however the prognosis for pa-
tients with metastases remains dismal [38].
There are few treatment options available for patients
with metastatic melanoma [39-42]. Recently, immuno-
therapy has shown promising results. In particular, ipili-
mumab, a human monoclonal antibody that blocks
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4),
has been associated with improved survival in patients
with metastatic melanoma [43]. Targeted therapy for pa-
tients with specific oncogenic mutations including BRAF
ab
Figure 1 Waterfall plots of metabolic response by lesion (a) and patient (b). Three subjects were classified as PMD based on the presence
of new lesions rather than % change SUVmax & have not been included in the waterfall plot above.
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a selective inhibitor of the BRAF serine-threonine kinase
enzyme has been linked to improved rates of overall
survival in patients with the BRAF V600E mutation [44].
KIT mutations have been found in the rare subgroup of
patients with mucosal melanoma, acral melanoma and
melanoma arising on chronically sun damaged skin, which
has raised the possibility of utilizing imatinib mesylate for
targeted therapy in these types of melanoma.
Imatinib mesylate is a tyrosine kinase inhibitor that
has previously been used to treat patients with GIST
[14,15]. These patients have a spectrum of neoplastic
disease ranging from benign to malignant, depending on
the tumor size, mitotic activity, anatomic site of origin
and the presence of a KIT mutation [45]. It is thought
that the KIT mutation promotes activation of tyrosine
kinase and results in tumorigenesis [13]. Unfortunately,
patients often develop secondary resistance to imatinib
mesylate within 2 years of treatment, likely due to the
presence of new KIT mutations in existing tumor cells.
Although 18F-FDG-PET/CT is not used to make theinitial diagnosis, it is helpful for monitoring therapy
response and can detect therapy resistant tumors by
demonstrating re-emergence of glycolytic activity and
resulting increased FDG uptake. 18F-FDG-PET/CT has
been used to evaluate response to molecular targeted
therapy in several cancers including melanoma [46].
In our study, the median TTP for patients with melan-
oma and a KIT genetic aberration (mutation or amplifi-
cation) was 4.7 months (95% CI: 1.3 to 7.4 months) and
was independent of melanoma type (log-rank p = 0.98)
or KIT aberration sub-type (log-rank p = 0.20). On 18F-
FDG-PET/CT there was a spectrum of disease response
to therapy at 1 month, as shown in Figure 1. Five of 17
patients (29%) responded to therapy, 5 of 17 patients
(29%) had stable disease and 7 of 17 patients (41%)
showed disease progression. As shown in Figure 3, the
metabolic response to therapy on 18F-FDG-PET/CT
could be used to detect therapy-resistant tumors. Specif-
ically, patients with progressive metabolic disease on
18F-FDG-PET/CT had a median TTP on anatomic im-
aging that was approximately 3.3 months shorter than
Figure 2 Representative 18F-FDG-PET/CT images showing progression in a patient without an exon 11 KIT mutation (a-d) and response in
a patient with an exon 11 KIT mutation (e-h) at baseline (a-b, e-f) and after 1 month of therapy (c-d, g-h). Red arrows point to sites of disease.
Reprinted with permission. © (2013) American Society of Clinical Oncology. All rights reserved. From: Hodi S, et al. J Clin Oncol. 31(26), 2013:3182-3190.
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Further, the overall survival of patients with progressive
disease on 18F-FDG-PET/CT was approximately 3 months
shorter than patients with SMD or PMR. This modest im-
provement in overall survival following metabolic responseto therapy may be due, in part, to secondary drug
resistance.
Tumor metabolic change on 18F-FDG-PET/CT was
also associated with KIT mutational status. The majority
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exon 11 had PMD. All of the patients with both PMR
and anatomic PR had a KIT mutation in exon 11.
The principal limitation of this study is the sample size.
Only 17 patients had evaluable 18F-FDG-PET/CT at base-
line and after 1 month of therapy and only 5 patients had
a KIT mutation in exon 11. Three of 5 patients with a KIT
mutation (60%) had the L576P mutation, which the litera-
ture suggests may have only limited response to imatinib
therapy. Although 12 patients did not have a KIT muta-
tion in exon 11, several of these patients had KIT amplifi-
cation. The overall survival was only slightly lower for
patients with KIT amplification compared with patients
who had a KIT mutation. Nevertheless, our results suggesta significant correlation between metabolic response and
exon 11 KIT mutation and suggest that metabolic change
on 18F-FDG-PET/CT may detect therapy-resistant disease.
Evaluation of a larger patient population will be needed to
confirm the statistical significance of the parameters we
have studied.
Conclusions
Metabolic response by 18F-FDG-PET/CT is associated
with exon 11 KIT mutational status in patients with
mucosal melanoma, acral melanoma or melanoma aris-
ing on chronically sun damaged skin treated with ima-
tinib. 18F-FDG-PET/CT may be a predictor of clinical
outcome, although a larger study is needed to verify this.
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